ArticleBiomaterials2019
Zwitterionic Janus Dendrimer with distinct functional disparity for enhanced protein delivery.
Article in Biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 54 citations in OpenAlex.
- Enhancing Peptide Hydrophilicity of SPPS-Derived Peptides Using Fmoc Noncanonical Amino Acids: A Review.ACS biomaterials science & engineering · 2026Review
- Telodendrimer nanotrap for selective cytokine removal from sepsis patient plasma.Frontiers in immunology · 2026Article
- Harnessing Telodendrimer Nanotraps in Nanogels for Systemic Immune Modulation in Sepsis Treatment.ACS pharmacology & translational science · 2025Article
- Extracellular vesicles isolation: a focus on magnetic beads-assisted platforms.Frontiers in bioengineering and biotechnology · 2025Review
- Sparstolonin B nano-formulation attenuates LPS-induced lung injury.Frontiers in pharmacology · 2025Article
- Unveiling cytokine charge disparity as a potential mechanism for immune regulation.Cytokine & growth factor reviews · 2024Review
- Telodendrimer functionalized hydrogel platform for sustained antibiotics release in infection control.Acta biomaterialia · 2024Article
- In Vivo Applications of Dendrimers: A Step toward the Future of Nanoparticle-Mediated Therapeutics.Pharmaceutics · 2024Review
- Engineering Nanotrap Hydrogel for Immune Modulation in Wound Healing.Macromolecular rapid communications · 2023Article
- Properties and Bioapplications of Amphiphilic Janus Dendrimers: A Review.Pharmaceutics · 2023Review
- Hybrid Molecules Consisting of Lysine Dendrons with Several Hydrophobic Tails: A SCF Study of Self-Assembling.International journal of molecular sciences · 2023Article
- Molecular dynamics simulation insights into the cellular uptake of elastic nanoparticles through human pulmonary surfactant.RSC advances · 2022Article
- Dendrimer-based drug delivery systems: history, challenges, and latest developments.Journal of biological engineering · 2022Review
- Facial Solid-Phase Synthesis of Well-Defined Zwitterionic Amphiphiles for Enhanced Anticancer Drug Delivery.Molecular pharmaceutics · 2021Article
- Antifouling Strategies of Nanoparticles for Diagnostic and Therapeutic Application: A Systematic Review of the Literature.Nanomaterials (Basel, Switzerland) · 2021Review
- Hypoxia-degradable and long-circulating zwitterionic phosphorylcholine-based nanogel for enhanced tumor drug delivery.Acta pharmaceutica Sinica. B · 2021Article
- Bistratal Au@BiBioactive materials · 2021Article
- A nanotrap improves survival in severe sepsis by attenuating hyperinflammation.Nature communications · 2020Article
- Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.Theranostics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
The development of a facile protein delivery vehicle is challenging and remains an unmet demand for clinical applications. The well-defined structure and functionality of a nanocarrier are highly desirable for the reproducibility and regulatory compliance. Herein, we report for the first time a novel Janus dendrimer (JD) system, comprised of two distinct dendrons with superior protein binding and protein repelling properties, respectively, for efficient spontaneous protein loading and enhanced in vivo protein delivery. Core-forming dendron is tethered with a combination of charged and hydrophobic moieties, which coat protein surface efficiently via the multivalent and synergistic interactions. Zwitterionic peripheries on the counter dendron endow the nanoparticle (<20 nm) with a highly hydrophilic and antifouling surface, which efficiently prevents serum protein adsorption and exchange as demonstrated in biolayer interferometry assay, therefore, reducing premature protein release. Surprisingly, JD nanocarriers containing biomimicking glycerylphosphorylcholine (GPC) surface significantly enhanced the intracellular uptake of protein therapeutics specifically in cancer cells, compared with zwitterionic carboxybetain (CB)-JD and PEGylated nanocarriers. The zwitterionic JD nanocarriers greatly prolonged the in vivo pharmacokinetic profiles of payloads relative to the PEGylated nanocarriers. Janus nanocarrier controlled the in vivo release of insulin and improved the blood sugar control in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.